Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing therapeutics for ALS and other neurodegenerative conditions. Its lead product, AMX0035, is a dual UPR-Bax apoptosis inhibitor designed for treating ALS using phenylbutyrate and taurursodiol. The company is based in Cambridge, Massachusetts, and was founded in 2013.